Moving together: Is there a global convergence in drug evaluation?

Biopharma companies have long been global entities, taking advantage of the benefits of debate and information sharing between sites in different cultures, countries and economic structures. In response to this, and to the progress in digital communications, payers are also becoming global players, sharing information and learning from one another.